Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announc

Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target

The SON-1010 studies have together enrolled 61 subjects, to date, as dose escalation continues in SB101 and SB221 at higher levelsPatients have received up to 25 cycles of SON-1010 as monotherapy and 10

Related Keywords

United States , Pankaj Mohan , Jack Yauch , Robert Wenham , Richard Kenney , Sonnet Biotherapeutics Holdings Inc , Nasdaq , Solebury Strategic Communications , Exchange Commission , Oncology At Moffitt Cancer Center , Genentech , Company Or Sonnet , Roche Group , Securities Exchange , Fully Human Albumin Binding , Secreted Protein Acidic , Safety Review Committees , Chief Medical , Response Evaluation Criteria , Solid Tumors , Moffitt Cancer Center , Lead Principal Investigator , Sonnet Founder , Chief Executive , Secreted Protein , Programed Death Ligand , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Ihr Portfolio ,